Fulgent Genetics Posts Mixed Q4, Issues Cautious 2026 Outlook
FULGENT GENETICS INC (NASDAQ:FLGT) reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a beat on adjusted earnings but falling short on revenue, while providing a full-year outlook for 2026 that signals continued challenges. The market's initial reaction was sharply negative, with shares trading down over 12% in pre-market activity following the release.
Fourth Quarter Performance Versus Estimates
The company's fourth-quarter results presented a split picture relative to analyst expectations. Revenue growth was positive but did not meet the bar set by Wall Street, while profitability on an adjusted basis came in stronger than anticipated.
- Revenue: Fulgent reported Q4 revenue of $83.3 million, representing a 9% increase year-over-year. This figure, however, fell short of the analyst consensus estimate of approximately $87.1 million.
- Earnings Per Share (Non-GAAP): The company reported non-GAAP income per share of $0.16. This significantly exceeded the modest analyst estimate of $0.03 per share.
The earnings beat was largely driven by management's adjustments, which excluded several significant one-time and non-cash expenses. On a GAAP basis, which includes these items, the company reported a substantial loss. The quarter was impacted by a $14.5 million one-time professional liability expense and increased acquisition-related costs, contributing to a GAAP net loss of $23.4 million, or ($0.76) per share.
Full-Year 2025 and Forward Guidance
For the full year 2025, Fulgent generated revenue of $322.7 million, a 14% increase over 2024. On a non-GAAP basis, full-year income was $13.2 million, or $0.42 per share, compared to a GAAP net loss of $60.5 million.
Management's outlook for 2026 is the focal point of investor concern. The company provided the following guidance:
- 2026 Revenue: Approximately $350 million.
- 2026 Non-GAAP Loss Per Share: Approximately ($1.45).
This guidance contrasts with existing analyst expectations, which had projected 2026 sales near $363.5 million and a much smaller non-GAAP loss per share of approximately ($0.33). In prepared remarks, Chief Financial Officer Paul Kim attributed the revenue guidance to "the impact of our largest customer moving a significant volume of its work in-house." He stated that strategic initiatives and contributions from recent acquisitions of Bako and Strata Dx are expected to help offset this impact in the second half of the year.
Market Reaction and Strategic Context
The steep pre-market decline in FLGT's share price reflects investor disappointment with the revenue miss for Q4 and, more critically, the substantially weaker-than-expected profit guidance for the coming year. The outlook suggests that investments, customer concentration headwinds, and ongoing development spending for its therapeutic pipeline will pressure earnings more heavily than previously modeled.
CEO Ming Hsieh highlighted progress in 2025 on the company's strategic roadmap, including momentum in laboratory services driven by AI and digital pathology investments, and advancement of its therapeutic candidates FID-007 and FID-022. The company ended the year with a strong balance sheet, featuring approximately $705.3 million in cash, cash equivalents, and marketable securities.
Conclusion
Fulgent Genetics' fourth quarter showcased underlying operational profitability on an adjusted basis but also revealed significant headwinds. While the core laboratory services business is growing, the loss of volume from a major customer and heavy investment in both acquisitions and therapeutic development are setting the stage for a difficult 2026 from a profitability standpoint. The company's robust cash position provides a runway to navigate this transition, but the market is clearly recalibrating expectations for near-term earnings.
For a detailed look at Fulgent's historical earnings and future estimates, visit the earnings and estimates page for FLGT.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.